El Cajon, CA, United States of America

Richard E Showalter

USPTO Granted Patents = 4 


 

Average Co-Inventor Count = 5.9

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • El Cajun, CA (US) (2019)
  • El Cajon, CA (US) (2017 - 2022)

Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Richard E Showalter

Introduction

Richard E Showalter is a notable inventor based in El Cajon, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of protein conjugates and cancer treatment methods. With a total of 4 patents, his work has the potential to impact therapeutic approaches for various diseases.

Latest Patents

Showalter's latest patents include innovative conjugates of arginine deiminase (ADI) and Tumor Necrosis Factor (TNF) superfamily ligands. These conjugates are designed for specific applications in cancer treatment. Additionally, he has developed arginine deiminase proteins that exhibit reduced cross-reactivity with anti-ADI-PEG 20 antibodies, while maintaining functional characteristics comparable to or better than ADI-PEG 20. These advancements are crucial for treating arginine-dependent diseases, including cancer.

Career Highlights

Throughout his career, Richard E Showalter has worked with prominent companies such as Polaris Group and Tdw Group. His experience in these organizations has allowed him to refine his expertise in biotechnology and contribute to groundbreaking research.

Collaborations

Showalter has collaborated with notable professionals in the field, including Robert Almassy and James A Thomson. These partnerships have further enhanced his research and development efforts.

Conclusion

Richard E Showalter's innovative work in biotechnology, particularly in the realm of cancer treatment, showcases his dedication to advancing medical science. His patents and collaborations reflect a commitment to improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…